Startseite>>Natural Products>>Msr-Ratio

Msr-Ratio (Synonyms: Msr-green)

Katalog-Nr.GC61557

Msr-Ratio (Msr-grÜn) ist eine ratiometrische Fluoreszenzsonde der Methioninsulfoxid-Reduktase (Λex=375 nm, Λem=550 nm).

Products are for research use only. Not for human use. We do not sell to patients.

Msr-Ratio Chemische Struktur

Cas No.: 2290635-22-0

Größe Preis Lagerbestand Menge
5 mg
278,00 $
Auf Lager
10 mg
445,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Msr-Ratio (Msr-green) is a ratiometric fluorescent probe of methionine sulfoxide reductase (Λex=375 nm, Λem=550 nm). Msr-Ratio is used for monitoring the enzyme activity in vitro and in live cells[1].

Msr-Ratio is converted to its corresponding sulfide form by methionine sulfoxide reductase. Msr-Ratio displays favorable properties such as a nearly 400-fold fluorescence change, fast response rate (<30 min), large Stokes shift (120 nm), and green emission (550 nm)[1].There is a very weak background signal in live HL60 cells after the addition of Msr-Ratio. As the Msr-Ratio (10 μM) incubation time increased in cells from 0 to 8 h, the fluorescence signal constantly strengthened[1].

[1]. Liangwei Zhang, et al. A ratiometric fluorescent probe of methionine sulfoxide reductase with an improved response rate and emission wavelength. Chem Commun (Camb). 2019 Jan 29;55(10):1502-1505.

Bewertungen

Review for Msr-Ratio

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Msr-Ratio

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.